Organ Transplant Immunosuppressant Drugs Market To Reach $7.24 Billion By 2030

Organ Transplant Immunosuppressant Drugs Market Growth & Trends

The global organ transplant immunosuppressant drugs market size is estimated to reach USD 7.24 billion by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing patient population requiring organ transplantations and increasing approval of novel products are the factors driving the market growth. However, the high procedural cost of transplantations, the disproportion in the supply and demand for organs, and uncertain reimbursement scenario are the major factors restraining the market growth.

According to the Health Resources & Services Administration and the U.S. Department of Health and Human Services, more than 113,000 people were in need of transplants as of January 2019 and 36,528 transplants were performed in 2018. Hence, there is huge demand for organ transplants that will further boost the market. Kidney transplant held the largest market share in the transplant segment and is expected to retain its leading position through the forecast period. This can be attributed to increasing demand and comparatively better availability of kidneys than other organs.

Among the drug classes, the calcineurin inhibitors are expected to dominate the global organ transplant immunosuppressant drugs market through the forecast period. There are two drugs in this drug class, Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). Although these effective immunosuppressants have been used in kidney transplant recipients for more than 20 years, they hold extensive toxicity profiles. Asia Pacific is expected to show the highest CAGR, while North America is expected to hold the largest share during the forecast period.

 Request a free sample copy or view report summary: Organ Transplant Immunosuppressant Drugs Market Report

Organ Transplant Immunosuppressant Drugs Market Report Highlights

• Calcineurin inhibitors are expected to command the largest market share in the drug class segment. Calcineurin inhibitors inhibit the activation action of T-cells of the immune system by the enzyme calcineurin.

• Calcineurin inhibitors such as tacrolimus and cyclosporine are the cornerstone of immunosuppression for kidney transplantation. In more than 85% cases of kidney transplant, tacrolimus is prescribed as a part of the patients’ maintenance immunosuppressive regimen.

• Based on transplant type, the kidney transplant held the largest market share of 49.1% in 2024, due to the increasing demand for kidney replacement procedures

• Asia Pacific regional market is expected to demonstrate the fastest growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare infrastructure, and increasing demand for organ transplantations in the region.

Organ Transplant Immunosuppressant Drugs Market Segmentation

Grand View Research has segmented the global organ transplant immunosuppressant drugs market based on drug class, transplant type, and region:

Organ Transplant Immunosuppressant Drugs Class Outlook (Revenue, USD Million, 2018 - 2030)

• Calcineurin Inhibitors

• Antiproliferative Agents

• mTOR Inhibitor

• Steroids

• Other Drug Classes

Organ Transplant Immunosuppressant Drugs Transplant Type Outlook (Revenue, USD Million, 2018 - 2030)

• Kidney

• Liver

• Heart

• Lung

• Pancreas

• Other Transplant Types

Organ Transplant Immunosuppressant Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Organ Transplant Immunosuppressant Drugs Market

• Astellas Pharma d.o.o.

• Sanofi

• Accord Healthcare

• Novartis AG

• Viatris Inc.

• F. Hoffmann-La Roche Ltd

• GlaxoSmithKline plc.

• Veloxis Pharmaceuticals, Inc.

• Bristol-Myers Squibb Company